Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.

Journal of medicinal chemistry - 11 Nov 2010

Wang Xiaolun, Berger Dan M, Salaski Edward J, Torres Nancy, Dutia Minu, Hanna Cilien, Hu Yongbo, Levin Jeremy I, Powell Dennis, Wojciechowicz Donald, Collins Karen, Frommer Eileen, Lucas Judy

Abstract excerpt

Novel indazolylpyrazolo[1,5-a]pyrimidine analogues have been prepared and found to be extremely potent type I B-Raf inhibitors. The lead compound shows good selectivity against a panel of 60 kinases, possesses a desirable pharmacokinetic profile, and demonstrates excellent in vivo antitumor efficacy in B-Raf mutant xenograft models.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Neoplasm Transplantation

Share to Proto-Oncogene Proteins B-raf

Share to Pyrazoles

Share to Pyrimidines

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 20961062
DOI: 10.1021/jm1007566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.PMID 20961062Read ↗

Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.Semantic proximity Read ↗

2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFV600E/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments.Semantic proximity Read ↗

Recent advances in B-RAF inhibitors as anticancer agents.Semantic proximity Read ↗

Mutant B-Raf Kinase Inhibitors as Anticancer Agents.Semantic proximity Read ↗

New S-substituted-3-phenyltetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one scaffold with promising anticancer activity profile through the regulation and inhibition of mutated B-RAF signaling pathway.Semantic proximity Read ↗

Design, synthesis, and biological evaluation of new B-RafV600E kinase inhibitors.Semantic proximity Read ↗

Discovery of Substituted 1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyridine Derivatives as Potent and Selective FGFR Kinase InhibitorsSemantic proximity Read ↗

Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants.Semantic proximity Read ↗

Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases.Semantic proximity Read ↗

Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.Semantic proximity Read ↗

On the development of B-Raf inhibitors acting through innovative mechanisms.Semantic proximity Read ↗

Discovery of 2-Aminopyrimidine Derivatives as Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced hERG Inhibitory Activities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.